The protective effect of progesterone in treating brain injury has been firmly established but the inability to develop a product that can be used in the field by medical first responders and the absence of intellectual property covering a composition of progesterone have prohibited commercialization.
To address these deficiencies, Encore has developed ETI-411, a novel lyophilized, easy to reconstitute and administer IV progesterone formulation. The company is now seeking a development and commercialization partner to bring ETI-411 to market.
ETI-411 is based on a proprietary phospholipid nano-emulsion formulation that is composed entirely of natural or generally regarded as safe components.
Andrew Chen, chief scientific officer and inventor of the formulation said: “ETI-411 is a substantial improvement over the current means of delivering IV progesterone. It is supplied in a stable, lyophilized format that can be easily reconstituted and administered, making it ideal for first responders and ER personnel treating stroke and traumatic brain Injury victims.”